Teva Pharmaceutical Industries Limited (TEVA) Given “Hold” Rating at Jefferies Group LLC

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group LLC in a note issued to investors on Friday. They currently have a $33.00 target price on the stock. Jefferies Group LLC’s price target points to a potential upside of 1.48% from the company’s current price.

Several other analysts have also commented on TEVA. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday. Mizuho raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and upped their target price for the company from $25.00 to $30.00 in a research report on Thursday, June 15th. Vetr downgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 target price on the stock. in a research report on Thursday. Royal Bank Of Canada set a $38.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Friday, June 16th. Finally, BTIG Research reissued a “neutral” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, April 6th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $43.56.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.2568% during mid-day trading on Friday, hitting $32.6035. The company’s stock had a trading volume of 4,986,804 shares. The company has a market cap of $33.13 billion, a P/E ratio of 417.9936 and a beta of 0.49. The firm’s 50-day moving average is $30.17 and its 200-day moving average is $33.07. Teva Pharmaceutical Industries Limited has a 12-month low of $27.60 and a 12-month high of $56.44.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, May 11th. The company reported $1.06 EPS for the quarter, meeting the consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. During the same quarter in the prior year, the business posted $1.20 EPS. The business’s revenue for the quarter was up 17.0% compared to the same quarter last year. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.78 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 22nd. Stockholders of record on Monday, June 5th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date was Thursday, June 1st. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently 5,802.90%.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Given “Hold” Rating at Jefferies Group LLC” was first published by sleekmoney and is the property of of sleekmoney. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://sleekmoney.com/teva-pharmaceutical-industries-limited-teva-given-hold-rating-at-jefferies-group-llc/1935368.html.

Large investors have recently bought and sold shares of the stock. Schulhoff & Co. Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares in the last quarter. Heritage Investors Management Corp raised its position in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares in the last quarter. Bank Hapoalim BM raised its position in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares in the last quarter. M Holdings Securities Inc. bought a new position in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth $491,000. Finally, Lincluden Management Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the fourth quarter. Lincluden Management Ltd. now owns 58,854 shares of the company’s stock worth $2,133,000 after buying an additional 4,272 shares in the last quarter. Hedge funds and other institutional investors own 56.26% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/teva-pharmaceutical-industries-limited-teva-given-hold-rating-at-jefferies-group-llc/1935368.html

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *